Literature DB >> 23250354

Guideline on the requirements of external quality assessment programs in molecular pathology.

J Han van Krieken1, Nicola Normanno, Fiona Blackhall, Elke Boone, Gerardo Botti, Fatima Carneiro, Ilhan Celik, Fortunato Ciardiello, Ian A Cree, Zandra C Deans, Anders Edsjö, Patricia J T A Groenen, Outi Kamarainen, Hans H Kreipe, Marjolijn J L Ligtenberg, Antonio Marchetti, Samuel Murray, Frank J M Opdam, Scott D Patterson, Simon Patton, Carmine Pinto, Etienne Rouleau, Ed Schuuring, Silke Sterck, Miquel Taron, Sabine Tejpar, Wim Timens, Erik Thunnissen, Peter M van de Ven, Albert G Siebers, Elisabeth Dequeker.   

Abstract

Molecular pathology is an integral part of daily diagnostic pathology and used for classification of tumors, for prediction of prognosis and response to therapy, and to support treatment decisions. For these reasons, analyses in molecular pathology must be highly reliable and hence external quality assessment (EQA) programs are called for. Several EQA programs exist to which laboratories can subscribe, but they vary in scope, number of subscribers, and execution. The guideline presented in this paper has been developed with the purpose to harmonize EQA in molecular pathology. It presents recommendations on how an EQA program should be organized, provides criteria for a reference laboratory, proposes requirements for EQA test samples, and defines the number of samples needed for an EQA program. Furthermore, a system for scoring of the results is proposed as well as measures to be taken for poorly performing laboratories. Proposals are made regarding the content requirements of an EQA report and how its results should be communicated. Finally, the need for an EQA database and a participant manual are elaborated. It is the intention of this guideline to improve EQA for molecular pathology in order to provide more reliable molecular analyses as well as optimal information regarding patient selection for treatment.

Entities:  

Mesh:

Year:  2012        PMID: 23250354     DOI: 10.1007/s00428-012-1354-4

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  11 in total

1.  Quality assurance in immunohistochemistry: results of an interlaboratory trial involving 172 pathologists.

Authors:  Thomas Rüdiger; H Höfler; H-H Kreipe; H Nizze; U Pfeifer; H Stein; F E Dallenbach; H-P Fischer; M Mengel; R von Wasielewski; H K Müller-Hermelink
Journal:  Am J Surg Pathol       Date:  2002-07       Impact factor: 6.394

Review 2.  The genetic basis for cancer treatment decisions.

Authors:  Janet E Dancey; Philippe L Bedard; Nicole Onetto; Thomas J Hudson
Journal:  Cell       Date:  2012-02-03       Impact factor: 41.582

3.  The UK NEQAS for Molecular Genetics scheme for gastrointestinal stromal tumour: findings and recommendations following four rounds of circulation.

Authors:  Newton A C S Wong; Zandra C Deans; Simon C Ramsden
Journal:  J Clin Pathol       Date:  2012-06-09       Impact factor: 3.411

4.  Implementation of External Quality Assurance Trials for Immunohistochemically Determined Breast Cancer Biomarkers in Germany.

Authors:  Reinhard von Wasielewski; Claudia A Krusche; Joseph Rüschoff; Anette Fisseler-Eckhoff; Hans Kreipe
Journal:  Breast Care (Basel)       Date:  2008-04-15       Impact factor: 2.860

5.  EGFR and KRAS quality assurance schemes in pathology: generating normative data for molecular predictive marker analysis in targeted therapy.

Authors:  Erik Thunnissen; Judith V M G Bovée; Hans Bruinsma; Adriaan J C van den Brule; Winand Dinjens; Daniëlle A M Heideman; Els Meulemans; Petra Nederlof; Carel van Noesel; Clemens F M Prinsen; Karen Scheidel; Peter M van de Ven; Roel de Weger; Ed Schuuring; Marjolijn Ligtenberg
Journal:  J Clin Pathol       Date:  2011-10       Impact factor: 3.411

6.  External quality assessment for KRAS testing is needed: setup of a European program and report of the first joined regional quality assessment rounds.

Authors:  Ellen Bellon; Marjolijn J L Ligtenberg; Sabine Tejpar; Karen Cox; Gert de Hertogh; Karin de Stricker; Anders Edsjö; Vassilis Gorgoulis; Gerald Höfler; Andreas Jung; Athanassios Kotsinas; Pierre Laurent-Puig; Fernando López-Ríos; Tine Plato Hansen; Etienne Rouleau; Peter Vandenberghe; Johan J M van Krieken; Elisabeth Dequeker
Journal:  Oncologist       Date:  2011-03-26

7.  Mutation analysis of KRAS prior to targeted therapy in colorectal cancer: development and evaluation of quality by a European external quality assessment scheme.

Authors:  Elisabeth Dequeker; Marjolijn J L Ligtenberg; Sara Vander Borght; Johan H J M van Krieken
Journal:  Virchows Arch       Date:  2011-06-24       Impact factor: 4.064

8.  Inter-laboratory and inter-observer reproducibility of immunohistochemical assessment of the Ki-67 labelling index in a large multi-centre trial.

Authors:  Michael Mengel; Reinhard von Wasielewski; Birgitt Wiese; Thomas Rüdiger; Hans Konrad Müller-Hermelink; Hans Kreipe
Journal:  J Pathol       Date:  2002-11       Impact factor: 7.996

Review 9.  Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer.

Authors:  William Pao; Juliann Chmielecki
Journal:  Nat Rev Cancer       Date:  2010-10-22       Impact factor: 60.716

10.  Quality control in diagnostic molecular pathology in the Netherlands; proficiency testing for patient identification in tissue samples.

Authors:  F B J M Thunnissen; M G J Tilanus; M J L Ligtenberg; P M Nederlof; W N M Dinjens; E Meulemans; A J C Van den Brule; C J M van Noesel; W J F de Leeuw; E Schuuring
Journal:  J Clin Pathol       Date:  2004-07       Impact factor: 3.411

View more
  35 in total

Review 1.  Endorsing good quality assurance practices in molecular pathology: risks and recommendations for diagnostic laboratories and external quality assessment providers.

Authors:  Lien Tembuyser; Elisabeth M C Dequeker
Journal:  Virchows Arch       Date:  2015-08-26       Impact factor: 4.064

2.  Quality Assessment of Reporting Performance for EGFR Molecular Diagnosis in Non-Small Cell Lung Cancer.

Authors:  Yanxi Han; Rui Zhang; Guigao Lin; Kuo Zhang; Jiehong Xie; Jinming Li
Journal:  Oncologist       Date:  2017-07-12

Review 3.  The ins and outs of molecular pathology reporting.

Authors:  Véronique Tack; Kelly Dufraing; Zandra C Deans; Han J van Krieken; Elisabeth M C Dequeker
Journal:  Virchows Arch       Date:  2017-03-26       Impact factor: 4.064

Review 4.  A 2015 update on predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance.

Authors:  M Dietel; K Jöhrens; M V Laffert; M Hummel; H Bläker; B M Pfitzner; A Lehmann; C Denkert; S Darb-Esfahani; D Lenze; F L Heppner; A Koch; C Sers; F Klauschen; I Anagnostopoulos
Journal:  Cancer Gene Ther       Date:  2015-09-11       Impact factor: 5.987

5.  Evaluation of tacrolimus-related CYP3A5 genotyping in China: Results from the First External Quality Assessment Exercise.

Authors:  Guigao Lin; Xiao Zhang; Kuo Zhang; Yanxi Han; Liming Tan; Jinming Li
Journal:  J Clin Lab Anal       Date:  2018-04-30       Impact factor: 2.352

6.  External quality assessment unravels interlaboratory differences in quality of RAS testing for anti-EGFR therapy in colorectal cancer.

Authors:  Véronique Tack; Marjolijn J L Ligtenberg; Lien Tembuyser; Nicola Normanno; Sara Vander Borght; J Han van Krieken; Elisabeth M C Dequeker
Journal:  Oncologist       Date:  2015-02-05

7.  Absence of BRAF exon 15 mutations in multiple myeloma and Waldenström's macroglobulinemia questions its validity as a therapeutic target in plasma cell neoplasias.

Authors:  Eleftheria Hatzimichael; Samuel Murray; Evangelos Briasoulis
Journal:  Am J Blood Res       Date:  2013-05-05

8.  RAS testing for colorectal cancer patients is reliable in European laboratories that pass external quality assessment.

Authors:  V Tack; M J L Ligtenberg; A G Siebers; P D M Rombout; P D Dabir; R D A Weren; J H J M van Krieken; E M C Dequeker
Journal:  Virchows Arch       Date:  2018-01-15       Impact factor: 4.064

Review 9.  Next generation diagnostic molecular pathology: critical appraisal of quality assurance in Europe.

Authors:  Hendrikus J Dubbink; Zandra C Deans; Bastiaan B J Tops; Folkert J van Kemenade; S Koljenović; Han J M van Krieken; Willeke A M Blokx; Winand N M Dinjens; Patricia J T A Groenen
Journal:  Mol Oncol       Date:  2014-03-18       Impact factor: 6.603

10.  Evaluation of a worldwide EQA scheme for complex clonality analysis of clinical lymphoproliferative cases demonstrates a learning effect.

Authors:  Cleo Keppens; Elke Boone; Paula Gameiro; Véronique Tack; Elisabeth Moreau; Elizabeth Hodges; Paul Evans; Monika Brüggemann; Ian Carter; Dido Lenze; Maria Eugenia Sarasquete; Markus Möbs; Hongxiang Liu; Elisabeth M C Dequeker; Patricia J T A Groenen
Journal:  Virchows Arch       Date:  2021-03-08       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.